• Sanofi Pasteur has chosen VBI’s LPV™ technology to develop a more stable formulation of a key Sanofi Pasteur vaccine candidate.
  • The collaboration will leverage VBI’s LPV™ technology, which allows for the stabilization of vaccine antigens and biologics.

VBI has entered into a research collaboration with Sanofi Pasteur to apply VBI’s LPV™ (Lipid Particle Vaccine) formulation technology to further the development of a key Sanofi Pasteur vaccine candidate.

Under the collaboration agreement, Sanofi Pasteur will leverage VBI’s LPV™ technology and expertise to reformulate a Sanofi Pasteur vaccine candidate to provide improved stability. The collaboration provides Sanofi Pasteur with the option to acquire certain worldwide rights to use VBI’s LPV™ technology in its vaccines. The vaccine candidate and the terms of the agreement were not disclosed.“VBI is proud to be working with Sanofi Pasteur, a significant global vaccine manufacturer, to provide a more stable formulation of one of its key pipeline assets,” said Jeff Baxter, VBI’s President and CEO. “Our LPV™ technology has shown great promise in stabilizing vaccines and biologics of a variety of classes and targets. This collaboration reinforces the potential of our technology.”

Stability is a critical issue affecting vaccine potency, safety, and ultimately patient access. LPV™ technology has the potential to confer thermostability up to 40° C by using a proprietary process and lipids which surround and enclose the antigen (active component) of a vaccine or biologic. To learn more about VBI’s vaccine platforms, visit: https://www.vbivaccines.com/technology.